Yondelis trabectedin: Phase II started

PharmaMar said investigators began the open-label, European Phase II EORTC 1320 trial to compare 1.5 mg/m 2 IV Yondelis every 3 weeks vs. the standard of care based on the local investigator’s discretion in about 86 patients. Yondelis is marketed to treat advanced soft tissue sarcoma (STS) and relapsed ovarian cancer. ...